| Abstract No.: | A-B1037 |
| Country: | Canada |
| | |
| Title: | THE NEUROPROTECTIVE EFFECTS OF COLIVELIN ON HIPPOCAMPAL SYNAPTIC PLASTICITY |
| | |
| Authors/Affiliations: | 1 Ning Ge*; 1 Kensuke Oikawa; 1 Dali Zhang; 1 Gary Odero; 1 Solmaz Nafez; 1 Benedict Albensi;
1 Department of Pharmacology and Therapeutics, Division of Neurodegenerative Disorders, Winnipeg, MB, Canada
|
| | |
| Content: | Objectives: Alzheimer’s disease (AD) is a debilitating illness, which affects behavior, personality and memory. In addition, it is a progressive neurodegenerative disorder associated with specific neuropathological hallmarks, such as amyloid B-peptide (AB) plaques and neurofibrillary tangles. Recent therapeutic strategies for AD have focused on the use of putative neuroprotective agents, which can decrease AB levels, several of which have also been found to regulate synaptic activity. Colivelin is a novel synthetic hybrid peptide that has been shown to have neuroprotective effects against familial AD (FAD) genes and AB peptides in vitro, ameliorating functional memory impairment of mice induced soluble toxic amyloid-B in vivo.
Materials and Methods: Field excitatory postsynaptic potentials in the CA1 region of acute mouse hippocampal slices were recorded to monitor the potential role of colivelin on synaptic plasticity. Results: We found that the application of colivelin caused a significant enhancement (p< 0.05) of basal synaptic transmission at concentrations as low as 10 pM.
Conclusion: Our results indicate that colivelin may play a role in basal synaptic transmission at the Schaffer collateral-CA1 synapse through a presynaptic mechanism. Our study also suggests that colivelin may ameliorate cognitive dysfunction prior to the onset of AD pathology. |
| | |
| Back |
|
